Timing of Probiotic Administration with Antibiotics

Rationale for Concurrent Administration

The primary goal of probiotic supplementation during antibiotic therapy is to prevent opportunistic pathogens from exploiting the disrupted gut microbiota niches created by antibiotic use, according to the American Gastroenterological Association 1

Saccharomyces boulardii is the only single-strain probiotic demonstrating significant reduction in Clostridioides difficile-associated diarrhea (CDAD) incidence (RR 0.41; 95% CI 0.22-0.79), as recommended by the American Gastroenterological Association 1, 2
S. boulardii has a unique advantage: antibiotics do not kill yeast, allowing it to survive concurrent antibiotic exposure, as noted by the American Gastroenterological Association 1
A 2-strain combination of L. acidophilus CL1285 + L. casei LBC80R (RR 0.22; 95% CI 0.11-0.42) and a 3-strain combination of L. acidophilus + L. delbrueckii subsp bulgaricus + B. bifidum (RR 0.35; 95% CI 0.15-0.85) have demonstrated efficacy in preventing CDAD, according to the American Gastroenterological Association 1, 2
A 4-strain combination of L. acidophilus + L. delbrueckii subsp bulgaricus + B. bifidum + S. salivarius subsp thermophilus (RR 0.28; 95% CI 0.11-0.67) has also demonstrated efficacy in preventing CDAD, as recommended by the American Gastroenterological Association 1, 2

Probiotics are absolutely contraindicated in immunocompromised patients due to risk of fungemia or bacteremia, as stated by the World Journal of Emergency Surgery 3

For patients requiring antibiotic therapy, assess contraindications and select appropriate probiotic strain, prioritizing S. boulardii (1g/day) or evidence-based multi-strain combinations, according to the World Journal of Emergency Surgery 3 and the American Gastroenterological Association 1

The American Gastroenterological Association conditionally recommends S. boulardii for prevention of C. difficile infection in patients receiving antibiotics, with evidence showing a 59% reduction in C. difficile-associated diarrhea recurrence compared to placebo 4

Effective dosing in clinical studies typically involves 1g or 3×10¹⁰ CFU/day of S. boulardii 4
For maximum benefit, S. boulardii should be started at the beginning of antibiotic therapy and continued throughout the entire course of treatment 4

S. boulardii is contraindicated in immunocompromised patients due to the risk of fungemia 4
The overall quality of evidence supporting S. boulardii's effects on intestinal immune function is rated as low to moderate 4
While S. boulardii shows promise for various gastrointestinal conditions, its specific effect on sIgA levels should be considered as part of its broader immunomodulatory actions 5